Tranzyme Inc. announced that its diabetic gastroparesis treatment TZP-102 failed in a mid-stage clinical trial.
Tranzyme said that when patients took the drug once per day, it did not work better than a placebo at treating symptoms of the condition. The company said it is "disappointed" with the trial results, but said a second mid-stage trial will continue. In that trial, patients are taking TZP-102 three times a day, once before every meal. TZP-102 is the company's most advanced drug candidate.
Gastroparesis is a condition in which the stomach takes too long to clear out food. Tranzyme said it affects about 12% of people with diabetes, and causes nausea, vomiting, dehydration, and difficulty digesting food.
This is the company's second setback this year. In March, it revealed its drug ulimorelin had failed a clinical trial. The drug was designed to help patients recover their gastrointestinal function after surgery. At the time, ulimorelin was Tranzyme's most advanced experimental drug.
Date: November 15, 2012
Source: Associated Press